Abstract:The kynurenine pathway (KP) of tryptophan metabolism has emerged in recent years as a key regulator of the production of both neuroprotective (e.g. kynurenic and picolinic acid, and the essential cofactor NAD+) and neurotoxic metabolites (e.g. quinolinic acid, 3-hydroxykynurenine). The balance between the production of the two types of metabolites is controlled by key rate-limiting enzymes such as indoleamine-2,3-dioxygenase (IDO-1), and in turn, molecular signals such as interferon-γ (IFN-γ), which activate the KP metabolism of tryptophan by this enzyme, as opposed to alternative pathways for serotonin and melatonin production. Dysregulated KP metabolism has been strongly associated with neurological diseases in recent years, and is the subject of increasing efforts to understand how the metabolites are causative of disease pathology. Concurrent with these endeavours are drug development initiatives to use inhibitors to block certain enzymes in the pathway, resulting in reduced levels of neurotoxic metabolites (e.g. quinolinic acid, an excitotoxin and N-Methyl-d-Aspartate (NMDA) receptor agonist), while in turn enhancing the bioavailability of the neuroprotective metabolites such as kynurenic acid. Neurodegenerative diseases often have a substantial autoimmune or inflammatory component; hence a greater understanding of how KP metabolites influence the inflammatory cascade is required. Additionally, challenges exist in diseases like multiple sclerosis (MS) and motor neurone disease (MND), which do not have reliable biomarkers. Clinical diagnosis can often be prolonged in order to exclude other diseases, and often diagnosis occurs at an advanced state of disease pathology, which does not allow a lengthy time for patient assessment and intervention therapies. This review considers the current evidence for involvement of the KP in several neurological diseases, in biomarkers of disease and also the parallels that exist in KP metabolism with what is known in other diseases such as HIV, Alzheimer's disease/dementia, infection, immune privilege and cardiovascular disease. This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'.

Kynurenine-3-monooxygenase (KMO) Broadly Inhibits Viral Infections Via Triggering NMDAR/Ca2+ Influx and CaMKII/ IRF3-mediated IFN-β Production

Kynurenine‐3‐monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression

A Novel Causative Role of Imbalanced Kynurenine Pathway in Ulcerative Colitis: Upregulation of KMO and KYNU Promotes Intestinal Inflammation.

Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid

Kynurenine 3-Monooxygenase Upregulates Pluripotent Genes Through Β-Catenin and Promotes Triple-Negative Breast Cancer Progression.

Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases

3-Hydroxykynurenine targets kainate receptors to promote defense against infection

Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer

Mitochondrial Protein PINK1 Positively Regulates RLR Signaling.

Suppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma

Identification of Resting and Type I Ifn-Activated Human Nk Cell Mirnomes Reveals Microrna-378 and Microrna-30e As Negative Regulators of Nk Cell Cytotoxicity

Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation.

Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases

Biochemistry and structural studies of kynurenine 3-monooxygenase reveal allosteric inhibition by Ro 61-8048.

Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase

Channeling kynurenine

The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies

Kynureninase Contributes to the Pathogenesis of Psoriasis Through Pro-Inflammatory Effect.

Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities

Riok3 inhibits the antiviral immune response by facilitating TRIM40-mediated RIG-I and MDA5 degradation